Tonix Pharmaceuticals Q3 2026 net loss available to common stockholders widens 67% year over year to $53.3 million

• Tonix Pharmaceuticals’ third-quarter 2026 net loss available to common stockholders widened 67% year-over-year to $53.3 million.
• Net product revenue rose year-over-year to approximately $17.2 million.
• TONMYA prescriptions climbed 28% quarter-over-quarter to 16,375; its sales force expanded to approximately 150 representatives on September 1.
• Cash and cash equivalents totaled approximately $163 million as of September 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-050621), on November 09, 2026, and is solely responsible for the information contained therein.